Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant
As Perrigo Gains Market Share, CEO Expects Shortage To Continue Through 2022
Executive Summary
Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.
You may also be interested in...
Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’
Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow
“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.